Market Place
Sourcing Support
Ribon rids preclinical work, trims staff to focus on two PARP inhibitors
28 Jul 2023 //
ENDPTS
Ribon Doses First Patient in Phase 1 Clinical Study with RBN-3143
09 Mar 2023 //
BUSINESSWIRE
Ribon Therapeutics Announces $25 Million Equity Investment from Pfizer
30 Jan 2023 //
BUSINESSWIRE
Pfizer invests in Ribon Therapeutics; Argenx gets PDUFA date extension
30 Jan 2023 //
ENDPTS
Ribon Announces Acquisition of Pre-Clinical CD38 Program by Boehringer
29 Nov 2022 //
BUSINESSWIRE
Ribon Therapeutics Announces Presentation of Preclinical Data on RBN-3143
06 Sep 2022 //
BUSINESSWIRE
Ribon Tx Announces Presentations at the AACR
11 Apr 2022 //
BUSINESSWIRE
Ribon Tx Initiates Phase 1b/2 Study of RBN-2397+Pembrolizumab in SCC
29 Mar 2022 //
BUSINESSWIRE
Ribon taps former Novartis VP Raman as CEO
18 Feb 2022 //
FIERCEBIOTECH
Ribon Therapeutics Announces CEO Transition for Its Next Phase of Growth
17 Feb 2022 //
BUSINESSWIRE
Ribon Therapeutics Announces Publication in Cancer Cell of Pre-Clinical
23 Jul 2021 //
BUSINESSWIRE
Ribon raises $65M to take PARP7 inhibitor deeper into the clinic
14 Jul 2021 //
FIERCEBIOTECH
Ribon Therapeutics Secures $65 Million Financing
14 Jul 2021 //
BUSINESS WIRE
Ribon Therapeutics is looking to break the mold for PARP inhibitors
14 Jul 2021 //
ENDPTS
Ribon Therapeutics Secures $65 Million Financing
14 Jul 2021 //
BUSINESS WIRE
Ribon Therapeutics Appoints Paul Brannelly as Chief Financial Officer
28 Jun 2021 //
BUSINESSWIRE
Ribon Therapeutics Announces Presentation of RBN-2397 Data at 2021 ASCO Meeting
20 May 2021 //
BUSINESSWIRE
Ribon Announces Upcoming Presentation on RBN-2397 at the 2021 ASCO
29 Apr 2021 //
BUSINESSWIRE
Ribon Announces License Agreement with Ono Pharmaceutical Co., Ltd. to Develop
02 Feb 2021 //
BIOSPACE
Ribon to Present New Preclinical Data on its PARP7 Inhibitor - RBN-2397
15 May 2020 //
BUSINESSWIRE
Ribon to Present New Preclinical Data on its PARP7 Inhibitor - RBN-2397
15 May 2020 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.